Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India

Back Stocks profile

Stock analysis tool for investors

Marksans Pharma Ltd.

NSE: MARKSANS | BSE:524404

₹166.04 -0.40 (-0.24%) 1D

Pharmaceuticals & Biotechnology

Buy Sell
View detailed Technical chart

Open an Account with Bigul in 5 minutes

Performance

Today’s low

165.00

Today’s High

168.20

52W low

90.60

52W High

185.50

Open Price

166.50

Prev. Close

152.0500

Volume

797624.00

Value

132437488.96

Fundamentals

Market Cap Cr

7524.30

Price to Earnings

24.00

Price to Book Value

3.60

Dividend Yield

0.00

PE to Growth

1.30

Op Revenue TTM Cr

2177.41

Net Profit TTM Cr

313.70

Cash From Operating Activity Cr

230.41

Return on Equity %

15.19

EMA & SMA

Bullish Moving Averages

16

Bearish Moving Averages

0

5Day EMA

164.9

10Day EMA

163.3

12Day EMA

162.9

20Day EMA

161.6

26Day EMA

161.2

50Day EMA

160.3

100Day EMA

157.2

200Day EMA

145.4

5Day SMA

164.4

10Day SMA

163.4

20Day SMA

160.5

30Day SMA

159.3

50Day SMA

161.3

100Day SMA

158.4

150Day SMA

158.6

200Day SMA

147.6

DELIVERY AND VOLUME

DAILY AVG. DELIVERY VOLUME %

04 Jul, 2024

54.1

Week

42

Month

48.1

LEGEND

Positive Indicator

Neutral Indicator

Negative Indicator

RESISTANCE AND SUPPORT

166.42

PIVOT

First Resistance

167.81

Second Resistance

169.57

Third Resistance

170.96

First Support

164.66

Second Support

163.27

Third Support

161.51

Relative Strength Index

57.76

Money Flow Index

72.49

MACD

1.66

MACD Signal

0.79

Average True Range

5.55

Average Directional Index

13.48

Rate of Change (21)

17.34

Rate of Change (125)

0.48

Commodity Channel Index

123.2

Williams %R

-23.5

BETA

1 Month

0.71

3 Month

0.64

1 Year

0.96

3 Year

0.43

PRICE CHANGE ANALYSIS

↑ 2.47%

1 Week

Low

High

158.22

168.8

↑ 13.92%

1 Month

Low

High

130

168.8

↑ 2.3%

3 Months

Low

High

130

185.5

↓ -5.31%

6 Months

Low

High

130

185.5

↑ 79.02%

1 Year

Low

High

90.6

185.5

Indicator Mar 2024 Dec 2023 Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021 Sep 2021 Graph
Total Qtr Revenue cr 237.39 242.69 220.60 214.66 157.35 188.46 191.29 178.58 183.93 178.00 177.45
Operating Expenses Qtr 191.29 199.39 167.37 155.28 130.34 148.93 136.49 147.54 149.41 138.12 134.92
Operating Profit Qtr 33.91 41.98 37.30 26.76 22.71 23.82 33.77 11.61 26.87 27.82 33.93
EBIDT Qtr Cr 46.10 43.30 53.23 59.38 27.01 39.53 54.80 31.04 34.52 39.88 42.53
Depreciation Qtr 7.47 8.43 8.50 4.72 3.51 4.18 4.53 4.52 4.61 4.52 4.30
Net Profit Qtr 32.99 25.29 31.29 44.19 17.81 25.62 40.23 19.21 21.43 26.06 27.60
Basic EPS Qtr 0.73 0.56 0.69 0.98 0.43 0.63 1.00 0.47 0.52 0.64 0.67
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Total Revenue Annual 915.35 715.69 700.54 630.70 433.59
Operating Expenses Annual Cr 713.34 563.30 544.57 485.84 361.93
Operating Profit Annual 139.94 91.90 113.72 113.71 71.49
Operating Profit Margin Annual % 15.29 12.84 16.23 18.03 16.49
Total Expenses Annual Cr 743.45 583.65 566.03 506.37 380.86
EBIDT Annual Cr 202.01 152.38 155.97 144.87 71.66
EBIDT Annual margin % 22.07 21.29 22.26 22.97 16.53
Depreciation 29.13 16.74 17.66 15.19 11.64
PAT Before ExtraOrdinary Items Annual Cr 133.76 102.87 103.99 98.38 37.90
Net Profit Annual 133.76 102.87 103.99 98.38 37.90
Basic EPS Annual 2.95 2.48 2.54 2.40 0.93
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Total ShareHolders Funds Annual 1222.70 1111.32 784.67 599.72 505.63
Minority Interest Liability Annual Cr - - - - -
Total Non Current Liabilities Annual Cr 20.89 17.00 14.41 23.94 24.79
Total Current Liabilities Annual Cr 272.44 216.54 166.53 94.90 69.37
Total Capital Plus Liabilities Annual Cr 1516.04 1344.86 965.61 718.55 599.78
Fixed Assets Annual 271.57 147.84 135.51 129.09 115.18
Total Non Current Assets Annual 568.33 431.10 375.75 369.32 355.73
Total Current Assets Annual 947.70 913.76 589.86 349.24 244.05
Total Assets Annual 1516.04 1344.86 965.61 718.55 599.78
Contingent Liabilities plus Commitments Annual Cr - 9.31 114.36 115.10 140.38
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Cash from Operating Activity Annual 34.05 51.73 50.97 107.07 118.01
Cash from Investing Activity Annual -114.22 -194.62 -8.39 8.82 -24.10
Cash from Financing Annual Activity -26.21 210.02 75.86 -13.53 -92.29
Net Cash Flow Annual - 67.12 118.44 102.36 1.63
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Book Value Per Share Annual 26.98 24.52 19.17 14.65 12.35
ROE Annual % 10.93 9.25 13.25 16.40 7.49
ROCE Annual % 13.90 12.02 17.30 20.79 11.31
Total Debt to Total Equity Annual 0.00 0.00 0.01 0.00 0.00
EBDIT Annual Margin % 23.67 23.25 23.69 24.16 16.53
Indicator Mar 2024 Dec 2023 Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021 Sep 2021 Graph
Total Qtr Revenue cr 576.54 590.93 550.23 510.13 496.99 497.48 466.72 450.27 433.39 374.69 369.77
Operating Expenses Qtr 450.37 453.11 417.29 398.07 376.43 403.19 372.30 360.91 354.40 304.83 301.10
Operating Profit Qtr 109.64 133.02 113.95 101.97 109.55 76.64 80.27 72.86 63.64 57.80 60.10
EBIDT Qtr Cr 126.17 137.82 132.94 112.06 120.56 94.30 94.42 89.36 78.98 69.86 68.67
Depreciation Qtr 21.05 22.00 17.55 13.66 13.94 12.74 14.05 11.12 21.36 8.56 7.39
Net Profit Qtr 78.29 83.23 83.52 68.66 81.93 63.41 61.25 59.72 29.65 48.27 46.29
Basic EPS Qtr 1.73 1.84 1.84 1.52 1.97 1.56 1.52 1.46 0.69 1.20 1.11
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Total Revenue Annual 2227.83 1911.45 1532.69 1382.88 1134.54
Operating Expenses Annual Cr 1718.83 1512.82 1231.96 1036.57 941.96
Operating Profit Annual 458.58 339.32 258.88 339.61 192.25
Operating Profit Margin Annual % 20.58 17.75 16.89 24.56 16.95
Total Expenses Annual Cr 1804.30 1573.80 1285.18 1080.71 977.36
EBIDT Annual Cr 509.00 398.63 300.73 346.30 192.58
EBIDT Annual margin % 22.85 20.86 19.62 25.04 16.97
Depreciation 74.27 51.85 44.78 36.15 26.66
PAT Before ExtraOrdinary Items Annual Cr 314.89 265.32 186.81 238.54 120.75
Net Profit Annual 313.70 266.31 186.81 238.54 120.75
Basic EPS Annual 6.92 6.41 4.51 5.76 2.86
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Total ShareHolders Funds Annual 2065.05 1745.16 1202.27 886.49 636.01
Minority Interest Liability Annual Cr 20.85 19.91 20.70 18.86 13.11
Total Non Current Liabilities Annual Cr 205.20 84.33 60.91 24.50 24.79
Total Current Liabilities Annual Cr 389.85 340.99 356.22 298.40 228.75
Total Capital Plus Liabilities Annual Cr 2680.95 2190.39 1640.10 1228.25 902.67
Fixed Assets Annual 745.85 457.69 400.86 321.04 302.72
Total Non Current Assets Annual 818.46 515.09 438.90 326.00 309.08
Total Current Assets Annual 1862.49 1675.30 1201.20 902.25 593.59
Total Assets Annual 2680.95 2190.39 1640.10 1228.25 902.67
Contingent Liabilities plus Commitments Annual Cr - 9.31 17.02 19.78 48.17
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Cash from Operating Activity Annual 230.41 237.41 99.26 0.00 209.94
Cash from Investing Activity Annual -140.84 -259.21 -41.69 0.00 -59.53
Cash from Financing Annual Activity -68.73 197.83 79.51 0.00 -90.15
Net Cash Flow Annual - 176.03 137.08 0.00 60.27
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Book Value Per Share Annual 46.03 38.95 29.88 22.12 15.86
ROE Annual % 15.19 15.25 15.53 26.90 18.98
ROCE Annual % 18.97 18.75 19.93 33.35 24.62
Total Debt to Total Equity Annual 0.01 0.02 0.03 0.02 0.03
EBDIT Annual Margin % 23.37 21.52 20.17 25.16 16.97
Name Holding Percent Holding Id Pledged % Locked %
Name Holding Percent Holding Id Pledged % Locked %
MARK SALDANHA 43.8 74543909 0 0.5
Name Holding Percent Holding Id
QUANT MUTUAL FUND - QUANT SMALL CAP FUND 2.79 74543913
ORBIMED ASIA IV MAURITIUS FVCI LIMITED 10.88 74543919
Name Holding Percent Holding Id
HUF 0.98 74543921
Ex-Date Dividend Amount Dividend Type Record Date Instrument Type
Jun 07, 2023 0.5 FINAL Jun 07, 2023 Equity Share
Aug 19, 2022 0.25 FINAL - Equity Share
Sep 15, 2021 0.25 FINAL - Equity Share
Sep 22, 2020 0.1 FINAL - Equity Share
Sep 19, 2019 0.05 FINAL - Equity Share
Sep 19, 2018 0.05 FINAL - Equity Share
Sep 19, 2017 0.05 FINAL - Equity Share
Sep 22, 2016 0.12 FINAL - Equity Share
Sep 23, 2015 0.12 FINAL - Equity Share
Sep 18, 2014 0.1 FINAL - Equity Share
Sep 16, 2002 - FINAL - Equity Share
Sep 05, 2001 - FINAL - Equity Share
Ex-Date Split Ratio Record Date
Mar 11, 2008 10:1 -
Ex-Date Purpose Notes
May 30, 2024 Audited Results & Final Dividend -
Feb 13, 2024 Quarterly Results -
Nov 09, 2023 Quarterly Results -
Aug 11, 2023 Quarterly Results -
May 30, 2023 Audited Results & Final Dividend -
Feb 13, 2023 Quarterly Results -
Jan 20, 2023 Others Inter alia, to consider and approve allotment of fully paid-up Equity Shares having face value of Re. 1/- each against the convertible warrants on preferential basis.
Nov 14, 2022 Quarterly Results -
Aug 13, 2022 Quarterly Results -
Jul 08, 2022 Buy Back of shares -
May 30, 2022 Audited Results & Final Dividend -
Feb 11, 2022 Quarterly Results -
Nov 10, 2021 Quarterly Results (Revised)
Aug 11, 2021 Quarterly Results -
Jul 23, 2021 To consider issue of Warrants -
Jun 15, 2021 To consider Issue of Warrants To consider issuance of convertible warrants on preferential basis.
May 31, 2021 Audited Results & Final Dividend -
Feb 08, 2021 Quarterly Results -
Nov 06, 2020 Quarterly Results -
Aug 04, 2020 Quarterly Results -
Jun 02, 2020 Audited Results & Final Dividend -
Feb 11, 2020 Quarterly Results -
Nov 12, 2019 Quarterly Results -
Aug 09, 2019 Quarterly Results -
May 29, 2019 Audited Results & Final Dividend -
Feb 08, 2019 Quarterly Results -
Nov 13, 2018 Half Yearly Results -
Aug 06, 2018 Unaudited Financial Results -
May 30, 2018 Audited Results & Dividend -
Feb 12, 2018 Quarterly Results -
Nov 13, 2017 Quarterly Results -
Aug 11, 2017 Quarterly Results -
May 29, 2017 Audited Results & Dividend -
Feb 06, 2017 Quarterly Results -
Nov 12, 2016 Quarterly Results -
Aug 13, 2016 Quarterly Results -
May 30, 2016 Audited Results & Dividend -
Feb 12, 2016 Quarterly Results -
Nov 10, 2015 Quarterly Results -
Aug 08, 2015 Quarterly Results -
May 30, 2015 Audited Results & Dividend -
Feb 07, 2015 Quarterly Results -
Oct 31, 2014 Quarterly Results -
Aug 12, 2014 Quarterly Results -
May 29, 2014 Audited Results & Dividend -
Feb 03, 2014 Quarterly Results -
Oct 31, 2013 Quarterly Results -
Jul 29, 2013 Quarterly Results -
May 27, 2013 Audited Results -
Feb 14, 2013 Quarterly Results -
Dec 14, 2012 To consider conversion of warrant&issue To consider conversion of warrants and issue and allot in lieu thereof 1,75,00,000 Equity Shares of Re. 1/- each to promoter on preferential allotment basis .
Nov 12, 2012 Quarterly Results -
Aug 14, 2012 Quarterly Results -
May 29, 2012 Audited Results -
Feb 13, 2012 Quarterly Results -
Nov 14, 2011 Quarterly Results -
Aug 12, 2011 Quarterly Results -
Jun 28, 2011 Audited Results -
May 28, 2011 Audited Results (Revised)
Feb 14, 2011 Quarterly Results (Revised)
Nov 15, 2010 Quarterly Results -
Aug 12, 2010 Audited & Quarterly Results -
May 07, 2010 Quarterly Results -
Apr 14, 2010 Conversion of Bonds The Board has converted the 1 Bond of US$ 1000 into 1,333 Equity Shares of Re. 1/- each & allotted to the concerned bond holder. Accordingly, Paid-up Equity Share Capital of the Company has increased.
Jan 29, 2010 Quarterly Results -
Dec 29, 2009 To consider Raising of Capital To raise capital through issue of Equity Shares and/or Equity Shares through depository receipts and/or FCCB's and/or any other CB's / Securities upto an amount not exceeding USD125 Million.
Oct 30, 2009 Quarterly Results & Others To raise capital through issue of Equity or Equity linked instruments upto Rs. 200 Crs & to restructure business model of the Company, hiving off API division of the Company.
Jul 31, 2009 Quarterly Results -
Jun 29, 2009 Audited Results -
Jan 31, 2009 Quarterly Results -
Oct 31, 2008 Quarterly Results -
Sep 23, 2008 Others To make allotment of 8400241 Equity Shares of Rs 1/- to M/s. Bamacle LLc on Preferential allotment basis, has been postponed to be held on September 23, 2008. (Revised)
Sep 16, 2008 Allotment of equity shares To allot 8400241 Equity shares of Re 1/- to M/s. Bamacle LLc on preferential allotment basis, if approved by the shareholders at the Extra Ordinary General Meeting to be held on September 10, 2008.
Sep 02, 2008 Audited Results & Others To consider and approve ESOP scheme for the employees of the Company & to fix the day, date, time and place of the Annual General Meeting.
Aug 27, 2008 Others To acquire entire shareholding of M/s. Relonchem Ltd.
Aug 11, 2008 Allotment of equity shares To allot 84,00,241 Equity shares of Rs 1/- each at a premium of Rs 19.12/- each of the Co., aggregating to an amount not exceeding Rs 16,89,87,000/- to Barnacle LLC, on preferential allotment basis.
Jul 31, 2008 Quarterly Results -
Apr 30, 2008 Quarterly Results -
Mar 27, 2008 To consider Redemption of CRPS To consider and approve redemption of Cumulative Redeemable Preference Shares issued by the Company and due for redemption on March 27, 2008.
Feb 29, 2008 Others To declare the results of the postal ballot and to decide the record date for the purpose of sub - division of the Equity shares of the Company.
Jan 25, 2008 Quarterly Results & Stock Split -
Oct 31, 2007 Quarterly Results -
Aug 31, 2007 Audited Results & Others 1. To consider appointment of Statutory Auditors of the Company. 2. To approve the draft of notice of the AGM. 3. Fix the day, date, time and place of the AGM. 4. To fix book Closure dates.
Jul 31, 2007 Quarterly Results -
Apr 30, 2007 Quarterly Results -
Jan 31, 2007 Quarterly Results -
Oct 30, 2006 Quarterly Results -
Jul 31, 2006 Quarterly Results -
Jun 29, 2006 Accounts, Amalgamation & Others 1. Approve issue of securities in the form of ADR / GDR / FCCB's. 2. Approve Amalgamation of Mark Remedies Ltd (Transferor Company) (100% subsidiary of the Company) with the Company (Transferee Co.)
Jan 31, 2006 Quarterly Results -
Oct 29, 2005 Quarterly Results -
Oct 18, 2005 Allotment of shares Allotment of shares to the shareholders of transferor Company pursuant to approved scheme of amalgamation.
Oct 06, 2005 To consider change of name of the co. To consider shifting of Registered office of the company & Decided to change the name of the company pursuant to Scheme of Amalgamation to M/s Marksans Pharma Ltd.
Jul 28, 2005 Quarterly Results -
Apr 28, 2005 Quarterly Results -
Apr 14, 2005 To consider issue of FCCB's/GDR To consider issue of Foreign Currency Convertible Bonds /GDR for financing acquisitions in the US and Europe or elsewhere.
Mar 18, 2005 Others To consider & approve Memorandum of Understanding (MoU) entered with Glenmark Laboratories Ltd .
Feb 24, 2005 Others To consider allotment of 1500000 shares to the holders of convertible share warrants.
Jan 27, 2005 Quarterly Results -
Dec 01, 2004 Others To consider allotment of 10,00,000 shares (first conversion) to the holders of Convertible share warrants.
Oct 28, 2004 Quarterly Results -
Aug 06, 2004 Others To consider issue of convertible share warrants on a private placement basis.
Jul 29, 2004 Quarterly Results -
Jan 19, 2004 Quarterly Results -
Oct 23, 2003 Quarterly Results -
Jul 31, 2003 Quarterly Results -
Jan 30, 2003 Quarterly Results -
Oct 30, 2002 Quarterly Results -
Oct 19, 2000 Quarterly Results -
Oct 07, 1999 Preferential Offer To allot 17,99,800 equity shares of Rs. 10/- each at a prem. of Rs. 6/- per
Jan 30, 1999 Quarterly Results -
Oct 31, 1998 Quarterly Results -
Jun 15, 1998 EGM -
Sep 05, 1997 Accounts & Dividend -
Ex-Date Bonus Ratio Record Date
02 Jul 2024

Marksans Pharma Rises As UK Regulator Approves New Drugs

 The company's subsidiary Relonchem, has received marketing authorisation for Rasagiline and Olmesartan drugs.
Bigul
02 Jul 2024

MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Press release intimating receipt of marketing authorization from UKMHRA.
Bigul
01 Jul 2024

MARKSANS PHARMA LTD. - 524404 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Details of issuance of duplicate share certificate issued by the Company as attached
Bigul
30 Jun 2024

MARKSANS PHARMA LTD. - 524404 - Closure of Trading Window

 Trading window for the designated persons of Marksans Pharma Limited will remain closed from 1st July, 2024 until 48 hours after announcement of Unaudited Financial Results for the quarter ended 30th June, 2024.
Bigul
05 Jun 2024

MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

 Kindly find attached transcript of earnings call Q4FY24
31 May 2024

Marksans Pharma Results Earnings Call for Q4FY24

 Conference Call with Marksans Pharma Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript.
Bigul
31 May 2024

MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

 Kindly find attached
Bigul
31 May 2024

MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Newspaper publication of Audited financial results for quarter and year ended March 31, 2024
Bigul
30 May 2024

Q4FY24 Quarterly & FY24 Annual Result Announced for Marksans Pharma Ltd.

 Pharmaceuticals company Marksans Pharma announced Q4FY24 & FY24 results: Q4FY24 Financial Highlights: Operating revenue was Rs 560.0 crore, up by 15.2% YoY driven by by volume gains, new launches, addition of new customers, and increase in our share with existing customers Gross profit was Rs 290.2 crore, up by 19.8% YoY with a Gross margin of 51.8% EBITDA was Rs 109.6 crore, grew by 0.1% with an EBITDA margin of 19.6% EPS was at Rs 1.73 FY24 Financial Highlights: Operating revenue was Rs 2,177.4 crore, up by 17.6% YoY US and North America business grew by 18.5% YoY UK and Europe grew by 22.9% YoY Gross profit was Rs 1,139.3 crore, up by 22.4% YoY with a Gross margin of 52.3%. EBITDA was Rs 458.6 crore, grew by 35.1% with an EBITDA margin of 21.1% EPS grew by 8.0% YoY to Rs 6.92 Mark Saldanha, Managing Director of the Company said “We are delighted to report a strong performance in FY24 in terms of both revenue and profitability. Our operating revenue for the year grew year-on-year by 18% and EBITDA increased by 35%, supported by new product launches, increase in market share, reduction in raw material prices and operating leverage. This year we have not only met but exceeded our revenue target of Rs 2,000 crore. We remain confident on delivering sustained long-term value for our shareholders, as we position ourselves strongly in terms of infrastructure, product mix and long-term customer relationships.” Result PDF
Bigul
30 May 2024

MARKSANS PHARMA LTD. - 524404 - Statement Of Deviation / Variation For Q4FY24

 Kindly find enclosed
See all News

FAQs

The latest market price of Marksans Pharma Ltd. on NSE was Rs. 166.04 as of today.

The opening share price of Marksans Pharma Ltd. was Rs. 166.50 as of today.

The 52-week high share price of Marksans Pharma Ltd. was Rs. 185.50.

The 52 week low share price of Marksans Pharma Ltd. was Rs. 90.60.

Marksans Pharma Ltd. has a market cap of Rs. 7524.30 crore as of today. Please refer to the Fundamentals section for further details.

The PE ratio of Marksans Pharma Ltd. is 1.30. Please refer to the Fundamentals section for further details.

The operating revenue for Marksans Pharma Ltd. in the last FY was Rs.  2177.41 crore. Please refer to the Financials section for further details.

The Net Profit for Marksans Pharma Ltd. in the last FY was Rs. 313.70 crore. Please refer to the Financials section for further details.

Please refer to Stock Ants, Bigul’s Community Access platform that aggregates tips and research from experts and provides real-time tracking to help investors validate, discover new investment ideas, and make informed decisions. Click here to learn more.

Please refer to Stock Ants, Bigul’s Community Access platform that aggregates tips and research from experts and provides real-time tracking to help investors validate, discover new investment ideas, and make informed decisions. Click here to learn more.

The latest dividend declared by Marksans Pharma Ltd. was on 2023-06-07 for Rs. 0.5 per share. According to today’s share price, the dividend yield of Marksans Pharma Ltd. stands at 0.00. Please refer to the Corporate Actions section for further details.

Please find Corporate actions section for more details.

The latest split issue declared by Marksans Pharma Ltd. was as of 2008-03-11. The split ratio declared in this issue was 10:1. Please refer to the Corporate Actions section for further details.

Please refer to Bigul Traders Corner, One Stop destination for different algo and non-algo trading strategies and tools meant for investors, traders, and strategists. Our qualified experts with rich experience in broking, financial analysis, and software development designed it in-house. Click here to learn more.

Please refer to JARVIS, which is Bigul’s AI Portfolio Manager Tool that uses artificial intelligence algorithms to make investment decisions in a portfolio. Click here to learn more.

Please refer to the News section for the latest news about Marksans Pharma Ltd..

Close

Let's Open Free Demat Account